|Title:||Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer||Authors:||Lu Y.-S.
|Issue Date:||2011||Journal Volume:||67||Journal Issue:||6||Start page/Pages:||1257-1263||Source:||Cancer Chemotherapy and Pharmacology||Abstract:||
Purpose: Docetaxel, capecitabine, and cisplatin are effective chemotherapeutic agents for breast cancer with significant synergistic cytotoxicity demonstrated by in vitro studies. The purpose of this study was to assess the efficacy of a combination of docetaxel, capecitabine, and cisplatin (TXP) in patients diagnosed with locally advanced breast cancer (LABC). Methods: Patients (n = 42) with chemotherapy-na?ve LABC (stage IIIa or IIIb) were enrolled. The chemotherapeutic regimen consisted of 4-6 cycles of intravenous docetaxel (60 mg/m2) and cisplatin (50 mg/m2) on day 1, plus oral capecitabine (1,800 mg/m2/day) on day 1-14, repeated every 3 weeks. Upon completion of therapy, the primary tumor was resected when not contraindicated. Results: Median patient age was 48.5 years (range 31-66 years). Median tumor size was 6.8 cm (range 2.7-15 cm), 29 patients were node-positive, and 12 patients were hormone receptor positive. A total of 216 cycles (median 5; range 3-6 cycles) were administered without prophylactic G-CSF. The predominant toxicities were grade 3/4 neutropenia (30%/28%) and no grade 3/4 thrombocytopenia, febrile neutropenia, or grade 4 non-hematological toxicities were observed. Grade 3 non-hematological toxicities included hand-foot syndrome (5.6%) and vomiting (0.5%). The overall clinical response rate was 97.6% (41/42). Six of the 42 patients (14.3%) achieved a complete pathological response. Of 22 patients who completed 6 cycles of combination treatment, the complete pathological response was 27.3% (6/22). Conclusions: A combination of TXP can be administered safely without prophylactic G-CSF, and appears to be an effective neoadjuvant regimen in patients with LABC. ? 2010 Springer-Verlag.
|ISSN:||0344-5704||DOI:||10.1007/s00280-010-1401-2||metadata.dc.subject.other:||capecitabine; cisplatin; docetaxel; granulocyte colony stimulating factor; hormone receptor; adult; advanced cancer; aged; alopecia; anemia; article; breast cancer; cancer adjuvant therapy; cancer combination chemotherapy; cancer size; clinical article; diarrhea; drug efficacy; edema; female; fever; hand foot syndrome; human; infection; leukopenia; lymph node metastasis; multicenter study; multiple cycle treatment; nail; nausea; nephrotoxicity; neurotoxicity; neutropenia; phase 2 clinical trial; priority journal; prospective study; side effect; stomatitis; thrombocytopenia; treatment response; vomiting; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Prospective Studies; Taxoids
|Appears in Collections:||腫瘤醫學研究所|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.